Revvity Inc. (NYSE:RVTY) Receives Consensus Rating of “Hold” from Analysts

Revvity Inc. (NYSE:RVTY) has earned a consensus recommendation of “Hold” from the thirteen analysts that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, six have given a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $113.9091.

A number of equities analysts have issued reports on RVTY shares. Barclays raised their price objective on shares of Revvity from $105.00 to $115.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Weiss Ratings reissued a “sell (d)” rating on shares of Revvity in a research note on Monday, December 29th. The Goldman Sachs Group initiated coverage on shares of Revvity in a report on Tuesday, December 9th. They issued a “neutral” rating and a $105.00 price target for the company. Bank of America downgraded shares of Revvity from a “buy” rating to a “neutral” rating and set a $110.00 price target for the company. in a research note on Monday, December 15th. Finally, Evercore ISI reissued an “outperform” rating on shares of Revvity in a research report on Monday, January 5th.

Institutional Investors Weigh In On Revvity

A number of hedge funds have recently added to or reduced their stakes in RVTY. CYBER HORNET ETFs LLC acquired a new position in shares of Revvity during the second quarter worth approximately $32,000. Cromwell Holdings LLC raised its holdings in Revvity by 141.4% during the fourth quarter. Cromwell Holdings LLC now owns 338 shares of the company’s stock worth $33,000 after buying an additional 198 shares during the last quarter. MUFG Securities EMEA plc acquired a new position in Revvity during the second quarter worth $34,000. UMB Bank n.a. lifted its stake in shares of Revvity by 138.8% in the second quarter. UMB Bank n.a. now owns 406 shares of the company’s stock valued at $39,000 after buying an additional 236 shares in the last quarter. Finally, CVA Family Office LLC grew its holdings in shares of Revvity by 79.0% during the second quarter. CVA Family Office LLC now owns 410 shares of the company’s stock valued at $40,000 after buying an additional 181 shares during the last quarter. Institutional investors and hedge funds own 86.65% of the company’s stock.

Revvity Stock Performance

RVTY stock opened at $116.64 on Friday. The firm has a market cap of $13.22 billion, a PE ratio of 58.61, a price-to-earnings-growth ratio of 3.57 and a beta of 1.05. The company has a current ratio of 1.75, a quick ratio of 1.44 and a debt-to-equity ratio of 0.36. The stock has a 50-day moving average price of $102.18 and a 200-day moving average price of $95.02. Revvity has a 1-year low of $81.36 and a 1-year high of $128.29.

Revvity (NYSE:RVTY) last released its earnings results on Monday, October 27th. The company reported $1.18 EPS for the quarter, topping the consensus estimate of $1.14 by $0.04. The business had revenue of $698.95 million during the quarter, compared to analysts’ expectations of $699.75 million. Revvity had a return on equity of 7.52% and a net margin of 8.44%.The firm’s revenue was up 2.2% on a year-over-year basis. During the same quarter last year, the firm posted $1.28 earnings per share. Revvity has set its FY 2025 guidance at 4.900-5.000 EPS. As a group, equities research analysts expect that Revvity will post 4.94 earnings per share for the current year.

Revvity declared that its board has authorized a share repurchase program on Monday, October 27th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the company to repurchase up to 8.7% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s board believes its shares are undervalued.

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.